Clinical Research Directory

Inclusion Criteria: * Healthy male and female participants aged 21 to 55 years at the time of the first dose administration. * Body Mass Index (BMI) between 18.5 and 30 kg/m², and body weight of at least 45 kg. * Participants must have vital signs within the normal range, as defined below, measured at pre-dose: * Blood Pressure: Systolic 100-130 mmHg, Diastolic 70-90 mmHg. * Pulse Rate: 60-100 beats per minute (bpm). * Body Temperature: 36.1-37.2 Exclusion Criteria: * Hypersensitivity to Enoxaparin or any of the formulation excipients * Contraindication to enoxaparin or related group of drugs, which includes but not limited to significant bleeding disorders, thrombocytopenia, blood-clothing disorders, and increased risk of bleeding. * History or presence of any medical condition or disease according to the opinion of the principal Investigator * History or presence of significant alcoholism or drug abuse in the past one year. * History or presence of heavy smoking (≥10 cigarettes or consumption of tobacco products and refusal to restrain from smoking or consumption of tobacco products for 48.00 hours before dosing until checkout of the study). * History or presence of significant renal, hepatobiliary, or liver impairment; a medical or familial history of seizures; significant asthma, urticaria, or other allergic reactions; or any other significant medical condition as determined by the Principal Investigator or their delegate. * History of difficulty with donating blood or difficulty in accessibility of veins * Use of any prescribed medication, OTC medicines or herbal medicines during the last two weeks preceding the first dosing * Participants who have any food allergy, intolerance, restriction, or special diet during the four weeks before screening * Participation in a drug research study within the past 2 months planned day of first dose administration * Donation of blood in the past 2 months before screening * Refusal to abstain from food (fasting) for at least ten hours before dosing * Refusal to abstain from alcohol or methylxanthine-containing beverages * Participants with a positive test for HBs-Ag, HIV-Ab, or HCV-Ab * Participant with a positive drug abuse test in urine at screening or at the time of check-in * Participant with abnormal baseline coagulation parameters, such as prolonged PT (if greater than 1.2 to 1.5 times the ULN of approximately 11 to 15 seconds), aPTT (if greater than 1.5 to 2.5 times the ULN of 25 to 40 seconds), or INR values (is above 1.4) outside the normal reference range. This is to minimize bleeding risk and confounding effects on study outcomes.